Personal tools

Wissenschaftliche Publikationen Bereich Rheumatologie

 2017

 Wissenschaftliche Artikel 

  • Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, Aringer M, Meißner Y, Zink A, Listing J. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis 2016; Jul 12 Epub. Impact factor 12,811.
  • Englbrecht M, Alten R, Aringer M, Baerwald CG, Burkhardt H, Eby N, Fliedner G, Gauger B, Henkemeier U, Hofmann MW, Kleinert S, Kneitz C, Krueger K, Pohl C, Roske AE, Schett G, Schmalzing M, Tausche AK, Tony HP, Wendler J. Validation of standardized questionnaires evaluating symptoms of depression in rheumatoid arthritis patients - approaches to screening for a frequent and yet underrated challenge. Arthritis Care Res (Hoboken) 2017; 69: 58-66. Impact factor 3,319.
  • van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, Askanase A, Balážová P, Bonfa E, Bootsma H, Boumpas D, Bruce I, Cervera R, Clarke A, Coney C, Costedoat-Chalumeau N, Czirják L, Derksen R, Doria A, Dörner T, Fischer-Betz R, Fritsch-Stork R, Gordon C, Graninger W, Györi N, Houssiau F, Isenberg D, Jacobsen S, Jayne D, Kuhn A, Le Guern V, Lerstrøm K, Levy R, Machado-Ribeiro F, Mariette X, Missaykeh J, Morand E, Mosca M, Inanc M, Navarra S, Neumann I, Olesinska M, Petri M, Rahman A, Rekvig OP, Rovensky J, Shoenfeld Y, Smolen J, Tincani A, Urowitz M, van Leeuw B, Vasconcelos C, Voss A, Werth VP, Zakharova H, Zoma A, Schneider M, Ward M. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017; 76: 554-561. Impact factor 12,811.
  • Boegemann M, Schlack K, Thomes S, Steinestel J, Rahbar K, Semjonow A, Schrader AJ, Aringer M, Krabbe LM. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone. Int J Mol Sci 2017; 18: pii: E380. Impact factor 3,226.
  • Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76: 960-977. Impact factor 12,811.
  • Meisterfeld S, Röber N, Conrad K, Beissert S, Aringer M, Günther C. A chronic recurrent disease course of dermatomyositis is associated with autoantibodies against transcriptional intermediary factor 1-γ. Br J Dermatol 2017; Mar 17 Epub. Impact factor 4,706.
  • Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, Johnson SR, Daikh D, Dörner T, Aringer M, Bertsias G; SLE Classification Criteria Steering Committee. Performance of Anti-nuclear Antibodies for Classifying Systemic Lupus Erythematosus: a Systematic Literature Review and Meta-regression of Diagnostic Data. Arthritis Care Res (Hoboken) 2017; May 23 Epub. Impact factor 3,319.
  • Proft F, Schulze-Koops H, Grunke M, Schrezenmeier E, Halleck F, Henes J, Unger L, Schmidt E, Fiehn C, Jacobi A, Iking-Konert C, Kneitz C, Schmidt RE, Bannert B, Voll RE, Fischer-Betz R, Kötter I, Tony HP, Holle J, Aringer M, Erler A, Behrens F, Burmester GR, Dörner T. Sicherheit und Wirksamkeitshinweise zum Off-label-Einsatz von Biologikatherapien nach Versagen konventioneller Therapien bei Patienten mit entzündlich rheumatischen Erkrankungen: Ergebnisse eines nationalen Registers (GRAID2). Z Rheumatol 2017 Jun 6 Epub. Impact factor 0,716.
  • Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 2017; 377: 317-328. Impact factor 72,406.
  • Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. Developing and Refining New Candidate Criteria for SLE Classification: An International Collaboration. Arthritis Care Res (Hoboken) 2017 Jul 10 Epub. Impact factor 3,319.
  • Schmitt J, Lange T, Günther KP, Kopkow C, Rataj E, Apfelbacher C, Aringer M, Böhle E, Bork H, Dreinhöfer K, Friederich N, Frosch KH, Gravius S, Gromnica-Ihle E, Heller KD, Kirschner S, Kladny B, Kohlhof H, Kremer M, Leuchten N, Lippmann M, Malzahn J, Meyer H, Sabatowski R, Scharf HP, Stoeve J, Wagner R, Lützner J. Indication Criteria for Total Knee Arthroplasty in Patients with Osteoarthritis - A Multi-perspective Consensus Study. Z Orthop Unfall 2017; 155: 539-548. Impact factor 0,618.
  • Engel B, Müller G, Roch B, Schröder HE, Aringer M, Bornstein SR, Morawietz H. Serum of patients with antiphospholipid syndrome induces adhesion molecules in endothelial cells. Atheroscler Suppl 2017; 30: 141-148. Impact factor 2,852.
  • Albrecht K, Huscher D, Buttgereit F, Aringer M, Hoese G, Ochs W, Thiele K, Zink A. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int 2017 Nov 9 Epub. Impact factor 1,824.
  • Schmajuk G, Hoyer BF, Aringer M, Johnson SR, Daikh DI, Dörner T; SLE classification criteria steering committee the international SLE expert panel of  the initiative. Multi-center Delphi Exercise Reveals Important Key Items for Classifying Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2017 Dec 29 Epub. Impact factor 3,319.
  • Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, Bhakta N, Storgard C, Baumgartner S, Saag K. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford) 2017; 56: 2170-2178. Impact factor 4,818.
  • Kiltz U, Alten R, Fleck M, Krüger K, Manger B, Müller-Ladner U, Nüsslein H, Reuss-Borst M, Schwarting A, Schulze-Koops H, Tausche AK, Braun J. [Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector : S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF]. Z Rheumatol 2017; 76: 118-124. Impact factor 0,716.
  • Ogdie A, Taylor WJ, Neogi T, Fransen J, Jansen TL, Schumacher HR, Louthrenoo W, Vazquez-Mellado J, Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea HK, Gerritsen M, Cagnotto G, Cavagna L, Lin C, Chou YY, Tausche AK, Lima Gomes Ochtrop M, Janssen M, Chen JH, Slot O, Lazovskis J, White D, Cimmino MA, Uhlig T, Dalbeth N. Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard. Arthritis Rheumatol. 2017 Feb; 69: 429-438. Impact factor 6,918.
  • Kroemer TM, Erler A, Tsourdi E, Gruber M, Tselmin S, Julius U, Aringer M, Hofbauer LC, Rachner TD. Immunoadsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report. Diabetes Care 2017 Dec 27 Epub. Impact factor 11,857.

 

  • Aringer M, Erler A. Recent advances in managing systemic sclerosis. F1000Res 2017; 6: 88. doi: 10.12688/f1000research.10022.1.

 

  • Aringer M, Leuchten N, Fischer-Betz R. Ausschleichen und Beenden von immunsuppressiven Therapien: Systemischer Lupus erythematodes. Z Rheumatol 2017; 76: 27-32. Impact factor 0,716.
  • Hedrich CM, Günther C, Aringer M. Morbus Still im Kindes- und Erwachsenenalter. Hautarzt 2017; 68: 497-511. Impact factor 0,661.

 

  • Aringer M. Janus kinase inhibitors clear to land: Janus kinase inhibitors in RA. Rheumatology (Oxford) 2017; Jun 13 Epub. Impact factor 4,818.
  • Hedrich CM, Günther C, Aringer M. Morbus Still im Kindes- und Erwachsenenalter. Z Rheumatol 2017; Jul 28 Epub. Impact factor 0,716.
  • Stummvoll G, Aringer M, Handisurya A, Derfler K. Immunoadsorption in autoimmune diseases affecting the kidney. Semin Nephrol 2017; 37: 478-487. Impact factor 3,598.

 

  • Aringer M, Karonitsch T. Januskinaseinhibitoren. J Miner Stoffwechs Muskuloskelet Erkrank 2017: 24: 76-80.

Buchkapitel 

  • Specker C, Aringer M. Stufendiagnostik. In Schneider-M Hrsg: Lupus erythematodes: Information für Erkrankte, Angehörige und Betreuende. Springer 2017; 19-22.
  • Aringer M, Specker C. Kriterien und Diagnose. In Schneider-M Hrsg: Lupus erythematodes: Information für Erkrankte, Angehörige und Betreuende. Springer 2017; 23-26.

2016

 Wissenschaftliche Artikel

 Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016; 75: 3-15. Impact factor 12,384.

  • Schmitt J, Schwarz K, Baurecht H, Hotze M, Fölster-Holst R, Rodríguez E, Lee YA, Franke A, Degenhardt F, Lieb W, Gieger C, Kabesch M, Nöthen MM, Irvine AD, McLean WH, Deckert S, Stephan V, Schwarz P, Aringer M, Novak N, Weidinger S. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. J Allergy Clin Immunol 2016; 137: 130-136. Impact factor 12,485.
  • Mauermann M, Hochauf-Stange K, Kleymann A, Conrad K, Aringer M. Parvovirus infection in early arthritis. Clin Exp Rheumatol 2016; 34: 207-213. Impact factor 2,495.
  • Riemekasten G, Aringer M, Baerwald CG, Meyer-Bahlburg A, Bergner R, Feuchtenberger M, Gebhardt C, Hellmich B, Keyßer G, Lorenz HM, Kneitz C, Witte T, Müller-Ladner U, Schneider M, Braun J, Rautenstrauch J, Specker C, Schulze-Koops  H. Rheumatologie - Integration in die studentische Ausbildung (RISA) – Zur aktuellen Struktur der internistischen Rheumatologie an deutschen Hochschulen (RISA III)]. Z Rheumatol 2016; 75: 493-501. Impact factor 0,569.
  • Dalbeth N, Schumacher HR, Fransen J, Neogi T, Jansen TL, Brown M, Louthrenoo W, Vazquez-Mellado J, Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea HK, Gerritsen M, Scire CA, Cavagna L, Lin C, Chou YY, Tausche AK, da Rocha Castelar-Pinheiro G, Janssen M, Chen JH, Cimmino MA, Uhlig T, Taylor WJ. Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. Arthritis Care Res (Hoboken) 2016; 68: 1894-1898. doi: 10.1002/acr.22896. PMID: 27014846 Impact factor 3,229.
  • Taylor WJ, Fransen J, Dalbeth N, Neogi T, Ralph Schumacher H, Brown M, Louthrenoo W, Vazquez-Mellado J, Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea HK, Gerritsen M, Scire CA, Cavagna L, Lin C, Chou YY, Tausche AK, da Rocha Castelar-Pinheiro G, Janssen M, Chen JH, Slot O, Cimmino M, Uhlig T, Jansen TL. Diagnostic Arthrocentesis for Suspicion of Gout Is Safe and Well Tolerated. J Rheumatol 2016; 43: 150-153. doi: 10.3899/jrheum.150684. Impact factor 3,690.
  • Langer M, Forkmann M, Richter U, Tausche AK, Sveric K, Christoph M, Ibrahim K, Günther M, Kolschmann S, Boscheri A, Barthel P, Strasser RH, Wunderlich C. Heart-type fatty acid-binding protein and myocardial creatine kinase enable rapid risk stratification in normotensive patients with pulmonary embolism. J Crit Care 2016; 35: 174-179. doi: 10.1016/j.jcrc.2016.05.014. PMID: 27481755 Impact factor 2,445.
  • Rasheed H, Phipps-Green AJ, Topless R, Smith MD, Hill C, Lester S, Rischmueller M, Janssen M, Jansen TL, Joosten LA, Radstake TR, Riches PL, Tausche AK, Lioté F, So A, van Rij A, Jones GT, McCormick SP, Harrison AA, Stamp LK, Dalbeth N, Merriman TR. Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout. Rheumatology (Oxford) 2016; 55: 1421-1430. doi: 10.1093/rheumatology/kew057. Impact factor 4,435.
  • Rasheed H, McKinney C, Stamp LK, Dalbeth N, Topless RK, Day R, Kannangara D, Williams K, Smith M, Janssen M, Jansen TL, Joosten LA, Radstake TR, Riches PL, Tausche AK, Lioté F, Lu L, Stahl EA, Choi HK, So A, Merriman TR. The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in European and Polynesian Sample Sets. PLoS One 2016; 11: e0147939. doi: 10.1371/journal.pone.0147939. Impact factor 3,234.
  • Henkemeier U, Alten R, Bannert B, Baraliakos X, Behrens F, Heldmann F, Kiltz U, Köhm M, König R, Leipe J, Müller-Ladner U, Rech J, Riechers E, Rubbert-Roth A, Schmidt RE, Schulze-Koops H, Specker C, Tausche AK, Wassenberg S, Witt M, Witte T, Zernicke J, Burkhardt H. [Do we still need clinical studies in rheumatology?]. Z Rheumatol 2016; 75: 4-10. doi: 10.1007/s00393-015-1687-x. German.  Impact factor 0,456.
  • Kiltz U, Alten R, Fleck M, Krüger K, Manger B, Müller-Ladner U, Nüßlein H, Reuss-Borst M, Schwarting A, Schulze-Koops H, Tausche A, Braun J.  [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)]. Z Rheumatol 2016; 75 (Suppl 2): 11-60. doi: 10.1007/s00393-016-0147-6. Impact factor 0,456.
  • de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, Cimmino MA, da Rocha Castelar Pinheiro G, Day R, Harrold LR, Helliwell P, Janssen M, Kerr G, Kavanaugh A, Khanna D, Khanna PP, Lin C, Louthrenoo W, McCarthy G, Vazquez-Mellado J, Mikuls TR, Neogi T, Ogdie A, Perez-Ruiz F, Schlesinger N, Ralph Schumacher H, Scirè CA, Singh JA, Sivera F, Slot O, Stamp LK, Tausche AK, Terkeltaub R, Uhlig T, van de Laar M, White D, Yamanaka H, Zeng X, Dalbeth N. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care Res (Hoboken) 2016; 68: 667-672. doi: 10.1002/acr.22741. Impact factor 3,229.
  • Peschke K, Achleitner M, Frenzel K, Gerbaulet A, Ada SR, Zeller N, Lienenklaus S, Lesche M, Poulet C, Naumann R, Dahl A, Ravens U, Günther C, Müller W, Knobeloch KP, Prinz M, Roers A, Behrendt R. Loss of Trex1 in dendritic cells is sufficient to trigger systemic autoimmunity. J Immunol 2016; 197: 2157-2166. doi: 10.4049/jimmunol.1600722. Impact factor 4,985.
  • Albus E, Sinningen K, Winzer M, Thiele S, Baschant U, Hannemann A, Fantana J, Tausche AK, Wallaschofski H, Nauck M, Völzke H, Grossklaus S, Chavakis T, Udey MC, Hofbauer LC, Rauner M. Milk Fat Globule-Epidermal Growth Factor 8 (MFG-E8) Is a Novel Anti-inflammatory Factor in Rheumatoid Arthritis in Mice and Humans. J Bone Miner Res 2016; 31: 596-605. doi: 10.1002/jbmr.2721. Impact factor 5,622.
  • Waldner MJ, Strangfeld A, Aringer M. Einfluss der Therapie auf das Krebsrisiko bei rheumatoider Arthritis – Pathophysiologische Grundlagen. Z Rheumatol 2016; 75: 13-21. Impact factor 0,569.
  • Boegemann M, Alten R, Aringer M, Zastrow S. Urologische Malignome und rheumatoide Arthritis. Z Rheumatol 2016; 75: 54-62. Impact factor 0,569.
  • Aringer M, Schneider M. Systemischer Lupus erythematodes. Dtsch Med Wochenschr. 2016; 141: 537-543. Impact factor 0,503.
  • Braun J, Krause A, Aringer M, Burmester G, Bessler F, Engel JM, Faubel U, Fischer-Betz R, Genth E, Gromnica-Ihle E, Hellmich B, Kötter I, Krüger K, Lakomek J, Lorenz HM, Manger B, Märker-Hermann E, Minden K, Müller-Ladner U, Rautenstrauch J, Rehart S, Riemekasten G, Rudwaleit M, Rüther W, Schett G, Schuch F, Schulze-Koops H, Specker C, Wassenberg S, Wiek D, Zink A, Schneider M. Europäische Versorgungsstandards für Menschen mit rheumatoider Arthritis – Übersetzung und Kommentierung der von der EULAR unterstützten Vorschläge des eumusc.net durch eine Task Force von DGRh und VRA mit Unterstützung der Deutschen Rheumaliga. Z Rheumatol 2016; 75: 416-428. Impact factor 0,569.
  • Taylor WJ, Fransen J, Dalbeth N, Neogi T, Schumacher HR, Brown M, Louthrenoo W, Vazquez-Mellado J, Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea HK, Gerritsen M, Scire C, Cavagna L, Lin C, Chou YY, Tausche AK, da Rocha Castelar-Pinheiro G, Janssen M, Chen JH, Slot O, Cimmino M, Uhlig T, Jansen TL. Performance of classification criteria for gout in early and established disease. Ann Rheum Dis 2016 Jan; 75: 178-82. Impact factor 9,082.
  • Aringer M, Dörner T, Leuchten N, Johnson SR. Toward new criteria for systemic lupus erythematosus-a standpoint. Lupus 2016; 25: 805-811. Impact factor 2,118.
  • Aringer M, Hedrich C, Tausche AK. Inflammasom und Gicht. Z Rheumatol 2016; 75: 537-541. Impact factor 0,569.
  • Tausche AK, Aringer M. Gicht. Z Rheumatol 2016; 75: 537-41. Impact factor 0,569.
  • Aringer M, Schneider M. Management des systemischen Lupus erythematodes. Internist (Berl) 2016; 57: 1052-1059. Impact factor 0,336.
  • Aringer M, Voll RE. Lupus erythematodes – Update 2016. Dtsch Med Wochenschr 2016; 141: 1785-1788. Impact factor 0,503.

Buchkapitel 

  • Tausche AK. Klinik und Diagnostik der Gicht. In: Alten R., Manger B. (Hrsg.) Gicht. Der aktuelle Wissenstand zu Ätiologie, Pathogenese, Diagnostik, Klinik und Therapie. De Gruyter  Berlin, Boston 2016; 18-27.
  • Aringer M. Methotrexat bei Spondylarthritiden, Vaskulitiden und Kollagenosen. In Müller-Ladner U & Rau R, Hrsg: Methotrexat bei Autoimmunerkrankungen – Moderne Therapiekonzepte in der Rehumatologie, Dermatologie und Gastroenterologie. 2. Auflage. Uni-Med Bremen, London, Boston 2016; 73-75.

2015

 Wissenschaftliche Artikel 

  • Günther C, Kind B, Reijns MA, Berndt N, Martinez-Bueno M, Wolf C, Tüngler V, Chara O, Lee YA, Hübner N, Bicknell L, Blum S, Krug C, Schmidt F, Kretschmer S, Koss S, Astell KR, Ramantani G, Bauerfeind A, Morris DL, Cunninghame Graham DS, Bubeck D, Leitch A, Ralston SH, Blackburn EA, Gahr M, Witte T, Vyse TJ, Melchers I, Mangold E, Nöthen MM, Aringer M, Kuhn A, Lüthke K, Unger L, Bley A, Lorenzi A, Isaacs JD, Alexopoulou D, Conrad K, Dahl A, Roers A, Alarcon-Riquelme ME, Jackson AP, Lee-Kirsch MA. Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest 2015; 125: 413-424.  Impact factor 13,765. PMID: 25500883
  • Aringer M, Smolen JS. Safety of off-label biologicals in systemic lupus erythematosus. Expert Opin Drug Saf 2015; 14: 243-251. Impact Factor 2,645. PMID: 25483011
  • Aringer M, Müller-Ladner U, Burkhardt H, Distler JH, Distler O, Graninger WB, Günther C, Hunzelmann N, Kiener H, Sticherling M, Sunderkötter C, Walker UA, Riemekasten G. Gemeinsame deutschsprachige Nomenklatur für die systemische Sklerose. Z Rheumatol 2015; 74: 100-103. Impact factor 0,447. PMID: 25805510
  • Fischer-Betz R, Aringer M. Lupustherapie in Bewegung: Die Richtung stimmt! Z Rheumatol 2015; 74: 182. Impact factor 0,447. PMID: 25854150
  • McKinney C, Stamp LK, Dalbeth N, Topless RK, Day RO, Kannangara DR, Williams KM, Janssen M, Jansen TL, Joosten LA, Radstake TR, Riches PL, Tausche AK, LiotéF, So A, Merriman TR. Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout. Arthritis Res Ther 2015; 17: 288. PMID: 26462562
  • Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Lioté F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2015; 74: 1789-1798. PMID: 26359487
  • Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Lioté F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ. 2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol 2015; 67: 2557-2568. PMID: 26352873
  • Taylor WJ, Fransen J, Jansen TL, Dalbeth N, Schumacher HR, Brown M, Louthrenoo W, Vazquez-Mellado J,  Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea H-K, Gerritsen M, Scire C, Cavagna L, Lin C, Chou Y-Y, Tausche AK, Vargas-Santos AB, Janssen M, Chen JH, Slot O, Cimmino MA, Uhlig T, Neogi T. Study for Updated Gout Classification Criteria (SUGAR): identification of features to classify gout. Arthritis Care Res (Hoboken) 2015; 67: 1304-1315. Impact factor 3,229.

Buchkapitel 

  • Hanson EP, Schwartz DM, Bonelli M, O’Shea JJ, Aringer M. Signal Transduction in immune cells. In Hochberg M, Silman A, Smolen S Weinblatt M, Weisman M, eds:  Rheumatology. Elsevier 2015; 113-118.
  • Aringer M, Schulze-Koops H. Immunologische Grundlagen. In Rehart S, Sell S, Hrsg: Orthopädische Rheumatologie. Georg Thieme 2015; 26-33.

 

2014  

Wissenschaftliche Artikel 

  • Unger L, Kampf S, Lüthke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology (Oxford). 2014; 53: 1630-1638. Impact factor 4,171.
  • Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, Aringer M, Wunderlich C. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatol Int 2014; 73: 349-357. Impact factor 2,214.
  • van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, Aringer M, Bootsma H, Boumpas D, Bruce IN, Cervera R, Clarke A, Costedoat-Chalumeau N, Czirják L, Derksen R, Dörner T, Gordon C, Graninger W, Houssiau F, Inanc M, Jacobsen S, Jayne D, Jedryka-Goral A, Levitsky A, Levy R, Mariette X, Morand E, Navarra S, Neumann I, Rahman A, Rovensky J, Smolen J, Vasconcelos C, Voskuyl A, Voss A, Zakharova H, Zoma A, Schneider M. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014; 73: 958-967. Impact factor 9,082
  • Leuchten N, Bauernfeind B, Kuttner J, Stamm T, Smolen JS, Pisetsky DS, Aringer M. Relevant concepts of functioning for patients with systemic lupus erythematosus identified in a delphi exercise of experts and a literature review. Arthritis Care Res (Hoboken) 2014; 66: 1895-1904. Impact factor 4,039
  • Tausche AK, Reuss-Borst M, Koch U. Urate lowering therapy with febuxostat in daily practice-a multicentre, open-label, prospective observational study. Int J Rheumatol 2014; Sep 3 Epub.
  • Aringer M, Schneider M. Recipes systemic lupus erythematosus. Z Rheumatol 2014; 73: 496-500. Impact factor 0,447.
  • Tausche AK, Aringer M. Chondrocalcinosis due to calcium pyrophosphate deposition (CPPD). From incidental radiographic findings to CPPD crystal arthritis. Z Rheumatol 2014; 73: 349-357. Impact factor 0,447.
  • Aringer M, Schneider M. Systemic lupus erythematosus - Standards in 2015. Dtsch Med Wochenschr 2014;139: 1813-1816. Impact factor 0,550.

 

  • Karonitsch T, Aringer M. Biologika bei SLE. Wien Med Wochenschr 2014 Nov 20 Epub
  • Aringer M, Smolen JS. Safety of off-label biologicals in systemic lupus erythematosus. Expert Opin Drug Saf 2014 Dec 6 Epub Impact Factor 2,645.

Bücher 

  • Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. 3. Auflage. Uni-Med Bremen, London, Boston 2014.
  • Tausche, A-K, Aringer M, Hrsg: Gicht – Neue Aspekte zur Pathogenese, Diagnostik und Therapie. Uni-Med Bremen, London, Boston 2014.

Buchkapitel 

  • Aringer M, Burkhardt H. Psoriasisarthritis, In Wozel G, Hrsg: Biologics in der Dermatologie. 3. Auflage. Uni-Med Bremen, London, Boston 2013; 41-43. (Nachtrag)
  • Aringer M. Golimumab. In Wozel G, Hrsg: Biologics in der Dermatologie. 3. Auflage. Uni-Med Bremen, London, Boston 2013; 122-125. (Nachtrag)
  • Aringer M. Belimumab, In Wozel G, Hrsg: Biologics in der Dermatologie. 3. Auflage. Uni-Med Bremen, London, Boston 2013; 161-164. (Nachtrag)
  • Aringer M, Schneider M. Basismaßnahmen bei SLE. In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. 3. Auflage. Uni-Med Bremen, London, Boston 2014; 32-34.
  • Aringer M, Graninger WB, Redlich K. Cyclophosphamid. In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. 3. Auflage. Uni-Med Bremen, London, Boston 2014; 35-38.
  • Aringer M, Dörner T. Belimumab. In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. 3. Auflage Uni-Med Bremen, London, Boston 2014; 47-50.
  • Dörner T, Aringer M. Immunadsorption, Off-label-Biologika und neue Wirkansätze. In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. 3. Auflage Uni-Med Bremen, London, Boston 2014; 52-58.
  • Hiepe F, Leuchten N, Aringer M. Konventionelle Therapie des nicht-renalen SLE – was ist gesichert? In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. 3. Auflage. Uni-Med Bremen, London, Boston 2014; 59-62.
  • Schröder H-E. Einleitung. In Tausche, A-K, Aringer M, Hrsg: Gicht – Neue Aspekte zur Pathogenese, Diagnostik und Therapie. Uni-Med Bremen, London, Boston 2014: 12-16.
  • Aringer M. Neue Aspekte zur Ätiologie und Pathogenese. In Tausche, A-K, Aringer M, Hrsg: Gicht – Neue Aspekte zur Pathogenese, Diagnostik und Therapie. Uni-Med Bremen, London, Boston 2014: 18-22.
  • Tausche A-K, Winzer M. Klinik. In Tausche, A-K, Aringer M, Hrsg: Gicht – Neue Aspekte zur Pathogenese, Diagnostik und Therapie. Uni-Med Bremen, London, Boston 2014: 24-30.
  • Tausche A-K, Schmidt WA. Diagnostik. In Tausche, A-K, Aringer M, Hrsg: Gicht – Neue Aspekte zur Pathogenese, Diagnostik und Therapie. Uni-Med Bremen, London, Boston 2014: 32 - 36.
  • Alten R, Bastigkeit M, Gola U, Tausche A-K. Therapie. In Tausche, A-K, Aringer M, Hrsg: Gicht – Neue Aspekte zur Pathogenese, Diagnostik und Therapie. Uni-Med Bremen, London, Boston 2014: 32 - 36.

2013  

Wissenschaftliche Artikel 

  • Thiele K, Huscher D, Bischoff S, Späthling-Mestekemper S, Backhaus M, Aringer M, Kohlmann T, Zink A. Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1194-1199. Impact factor 9,111
  • Hagenow, Seifert J, Zeissig A, Conrad K, Kleymann A, Aringer M. Clin Exp Rheumatol 2013; 31:213-218. Impact factor 2,655.
  • Fischer-Betz R, Specker C, Brinks R, Aringer M, Schneider M. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford) 2013 Jun; 52: 1070-1076. Impact factor 4,212.
  • Tausche AK, Gehrisch S, Panzner I, Winzer M, Range U, Bornstein SR, Siegert G, Wunderlich C, Aringer M. A 3-day delay in synovial fluid crystal identification did not hinder the reliable detection of monosodium urate and calcium pyrophosphate crystals. J Clin Rheumatol 2013; 19: 241-245. Impact factor 1,183.
  • Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, Aringer M, Wunderlich C. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatol Int 2013; Sep 12 Epub. Impact factor 2,214.
  • Witt M, Grunke M, Proft F, Baeuerle M, Aringer M, Burmester G, Chehab G, Fiehn C, Fischer-Betz R, Fleck M, Freivogel K, Haubitz M, Kötter I, Lovric S, Metzler C, Rubberth-Roth A, Schwarting A, Specker C, Tony HP, Unger L, Wassenberg S, Dörner T, Schulze-Koops H; German Registry of Autoimmune Diseases (GRAID) Investigators. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus 2013; 22: 1142-1149. Impact factor 2,783.
  • Aringer M, Fischer-Betz R, Hiepe F; Kommission Pharmakotherapie der DGRh. Statement on the use of mycophenolate mofetil for systemic lupus erythematosus. Z Rheumatol 2013; 72: 575-80. Impact factor 0,450.
  • Aringer M, Günther C, Lee-Kirsch MA. Innate immune processes in lupus erythematosus. Clin Immunol 2013; 147:216-222. Impact factor 3,771.
  • Aringer M, Vital E. Lots of autoantibodies equal lupus? Arthritis Res Ther 2013; 15: 102. Impact factor 4,302.
  • Hohenstein B, Bornstein SR, Aringer M. Immunoadsorption for connective tissue disease. Atherosclerosis Suppl 2013; 14: 185-189. Impact Factor 4,333.
  • Aringer M, Dörner T. Biosimilars: Current state of the build up to series production. Z Rheumatol 2013; 72: 873-877. Impact factor 0,450.
  • Mosca M, Tani C, Aringer M. Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal? Clin Exp Rheumatol 2013; 31: S71-4. Impact factor 2,655.
  • Stein NCG, Conrad K, Aringer M. Antibodies to ribosomal P in lupus psychosis resolving after rituximab plus cyclophosphamide – a case report. J Clin Cell Immunol 2013; 4: 5.

Buchkapitel 

  • Laurence A, Aringer M. Effector mechanisms in autoimmunity. In Rose NR, Mackay IR, eds: The autoimmune diseases. 5th edition. Elsevier 2013; 311-317.
  • Aringer M, Burkhardt H. Psoriasisarthritis, In Wozel G, Hrsg: Biologics in der Dermatologie. 3. Auflage. Uni-Med Bremen, London, Boston 2013; 41-43.
  • Aringer M. Golimumab. In Wozel G, Hrsg: Biologics in der Dermatologie. 3. Auflage. Uni-Med Bremen, London, Boston 2013; 122-125.
  • Aringer M. Belimumab, In Wozel G, Hrsg: Biologics in der Dermatologie. 3. Auflage. Uni-Med Bremen, London, Boston 2013; 161-164.

2012  

Wissenschaftliche Artikel 

  • Aringer M, Burkhardt H, Burmester GR, Fischer-Betz R, Fleck M, Graninger W, Hiepe F, Jacobi AM, Kötter I, Lakomek HJ, Lorenz HM, Manger B, Schett G, Schmidt RE, Schneider M, Schulze-Koops H, Smolen JS, Specker C, Stoll T, Strangfeld A, Tony HP, Villiger PM, Voll R, Witte T, Dörner T. Current state of evidence on "off label" therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria, and Switzerland - a consensus report. Lupus 2012; 21: 386-401. Impact factor 2,600.

 

  • Karonitsch T, Dalwigk K, Steiner CW, Blüml S, Steiner G, Kiener HP, Smolen JS, Aringer M. Interferon (IFN) signals and monocytic sensitization of the IFNγ signalling pathway in peripheral blood of rheumatoid arthritis patients. Arthritis Rheum 2012; 64: 400-408. Impact factor 8,435.
  • Cappelli S, Bellando Randone S, Martinović D, Tamas MM, Pasalić K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radić M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M,Ionescu R, Czirják L, Damjanov N, Rednic S, Matucci Cerinic M. "To Be or Not To Be," Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity. Semin Arthritis Rheum 2012; 41: 589-598. Impact factor 4,744.
  • Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dörner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, Jayne D, Boumpas DT. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-1782. Impact factor 9,082.
  • Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, Kötter I, Henes JC, Bergner R, Rubbert-Roth A, Specker C, Schulze-Koops H, Müller-Ladner U, Fleck M, Burmester GR, Hiepe F, Heitmann S, Aringer M, Fischer-Betz R, Dörner T, Tony HP.Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol 2012; 39: 2153-2156. Impact factor 3,551.
  • Schaller G, Dittrich P, Felizeter M, Gouya G, Leuchten N, Kapiotis S, Vcelar B, Vorauer-Uhl K, Wolzt M. Human pharmacokinetics of intravenous recombinant human Cu/Zn superoxide dismutase. Int J Clin Pharmacol Ther 2012; 50: 413-417. Impact factor 1,183.
  • Foocharoen C, Distler O, Becker M, Müller-Ladner U, von Mühlen C, Leuchten N,  Walker UA. Clinical correlations of hypocomplementaemia in systemic sclerosis: an analysis of the EULAR Scleroderma Trial and Research group (EUSTAR) database. Scand J Rheumatol 2012; 41: 243-246. Impact factor 2,594.
  • Wolzt M, Eriksson UG, Gouya G, Leuchten N, Kapiotis S, Elg M, Schützer KM, Zetterstrand S, Holmberg M, Wåhlander K. Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists. Thromb Res 2012; 129: e83-91. Impact factor 2,440.
  • Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, Khanna D. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes 2012; 10: 117.  Impact factor 2,11.
  • Günther C, Aringer M, Lochno M, Kämmerer E, Bauer A, Wozel G, Meurer M. TNF-alpha Blockade with Infliximab in a Patient with Lupus Erythematosus Profundus. Acta Derm Venereol 2012; 92: 401-403. Impact factor 3,176.

 

  • Aringer M, Strand V. Endpoints for randomised controlled trials in systemic lupus erythematosus. Clin Exp Rheumatol 2012; 30: 147-51. Impact factor 2,358.

 

  • Aringer M. Vaccination under TNF blockade - less effective, but worthwhile. Arthritis Res Ther 2012; 14: 117. Impact factor 4,357.
  • Tausche AK, Manger B, Müller-Ladner U, Schmidt B. Gout as a systemic disease. Manifestations, complications and comorbidities of hyperuricaemia. Z Rheumatol 2012; 71: 224-230. Impact factor 0,447.
  • Rauner M, Hofbauer LC, Aringer M. Local and systemic bone effects of rheumatoid arthritis. Z Rheumatol 2012; 71: 869-874. Impact factor 0,447.
  • Aringer M, Tony HP. Systemic disease rheumatoid arthritis. Z Rheumatol. 2012; 71: 840. Impact factor 0,447.
  • Rohleder N, Aringer M, Boentert M. Role of interleukin-6 in stress, sleep, and fatigue. Ann N Y Acad Sci 2012;1261: 88-96. Impact factor 2,847.

2011 

Wissenschaftliche Artikel 

  • Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Cervera R, Doria A, Jayne D, Khamashta MA, Kuhn A, Gordon C, Petri M, Schneider M, Shoenfeld Y, Smolen JS, Talarico R, Tincani A, Ward MM, Werth VP, Carmona L. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 2011; 10: 383-388. Impact factor 6,556.
  • Beyer C, Distler JH, Allanore Y, Aringer M, Avouac J, Czirják L, Cutolo M, Damjanov N, Del Galdo F, Fligelstone K, Guiducci S, Kowal-Bielecka O, van Laar JM, Martucci-Cerinic M, Müller-Ladner U, Riemekasten G, Tarner IH, Tyndall A, Kennedy AT, Valentini G, Vettori S, Walker UA, Denton C, Distler O for the EUSTAR Biobanking Group. Ann Rheum Dis 2011; 70:1178-1182. Impact factor 9,082.
  • Mosca M, Govoni M, Tomietto P, Aringer M, Boumpas D, Cervera R, Conti F, D'Cruz D, Doria A, De La Fuente D, Galeazzi M, Houssiau F, Huizinga TW, Khamashta MA, Ines L, Catia D, Couto M, Meroni P, Montecucco C, Norkuviene E, Riemekasten G, Rios V, Schneider M, Shoenfeld Y, Steup-Beekman G, Szmyrka-Kaczmarek M, Tani C, Tincani A, Tzioufas A, Voll R, Bencivelli W, Salaffi F, Bombardieri S. The development of a simple questionnaire to screen SLE patients for the presence of neuropsychiatric (NP) symptoms in routine clinical practice. Lupus 2011; 20: 485-492. Impact factor 2,600.
  • Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kötter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Müller-Ladner U, König R, Fiehn C, Burgwinkel P, Budde K, Sörensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dörner T; GRAID investigators. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011; 13: R75 Impact factor 4,357.
  • Iking-Konert C, Aringer M, Wollenhaupt J, Mosch T, Tuerk S, Feist E, Burmester GR. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis 2011; 70: 1986-1990. Impact factor 9,082.
  • Karonitsch T, Dalwigk K, Steiner CW, Blüml S, Steiner G, Kiener HP, Smolen JS, Aringer M. Interferon (IFN) signals and monocytic sensitization of the IFNγ signalling pathway in peripheral blood of rheumatoid arthritis patients. Arthritis Rheum 2011; Sep 27 Epub. Impact factor 8,435.
  • Cappelli S, Bellando Randone S, Martinović D, Tamas MM, Pasalić K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radić M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M,Ionescu R, Czirják L, Damjanov N, Rednic S, Matucci Cerinic M. "To Be or Not To Be," Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity. Semin Arthritis Rheum 2011; Sep 27 Epub. Impact factor 4,744.

 

  • Aringer M, Burkhardt H, Burmester GR, Fischer-Betz R, Fleck M, Graninger W, Hiepe F, Jacobi AM, Kötter I, Lakomek HJ, Lorenz HM, Manger B, Schett G, Schmidt RE, Schneider M, Schulze-Koops H, Smolen JS, Specker C, Stoll T, Strangfeld A, Tony HP, Villiger PM, Voll R, Witte T, Dörner T. Current state of evidence on "off label" therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria, and Switzerland - a consensus report. Lupus 2011; Nov 9 Epub. Impact factor 2,600.
  • Tausche AK, Wunderlich C, Aringer M. Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma. Case Report Med 2011;2011:397646 May 14. Epub
  • Aringer M, Smolen JS. Therapeutic blockade of TNF in SLE – promising or crazy? Autoimm Rev 2011 May 18 Epub. Impact factor 6,556.
  • Aringer M, Hiepe F. [Systemic lupus erythematosus.] Z Rheumatol 2011; 70: 313-323. Impact factor 0,447.
  • Aringer M, Bornstein SR. [Autoinflammatory aspects in internal medicine – therapeutic options. Akt Rheumatol 2011; 36: 242-245.
  • Müller-Ladner U, Panzner I, Kriegsmann J, Lange U, Tausche AK. [Gout - regardless of therapeutic options a "forgotten" disease]. Dtsch Med Wochenschr. 2011 Aug; 136: 1660-1664. Impact factor 0,500.

Buchkapitel 

  • Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. 2. Auflage. Uni-Med Bremen, London, Boston 2011. 95 Seiten.
  • Aringer M, Schneider M. Basismaßnahmen bei SLE. In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. 2. Auflage. Uni-Med Bremen, London, Boston 2011; 32-34.
  • Aringer M, Redlich K. Cyclophosphamid. In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. 2. Auflage. Uni-Med Bremen, London, Boston 2011; 35-38.
  • Dörner T, Aringer M. Belimumab, Off-label-Biologika und Immunadsorption. In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. 2. Auflage Uni-Med Bremen, London, Boston 2011; 46-51.
  • Hiepe F, Aringer M. Basistherapie des nicht-renalen SLE – was ist gesichert? In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. 2. Auflage. Uni-Med Bremen, London, Boston 2011; 52-55.
  • Stummvoll G, Aringer M. Systemischer Lupus erythematodes (SLE). In Dunky A, Graninger W, Herold M, Smolen J, Wanivenhaus A, Hrsg: Praktische Rheumatologie. Fünfte, aktualisierte und erweiterte Auflage. Springer Wien, New York 2011; 319-331.
  • Aringer M, Stummvoll G. Mixes connective Tissue Disease (MCTD). In Dunky A, Graninger W, Herold M, Smolen J, Wanivenhaus A, Hrsg: Praktische Rheumatologie. Fünfte, aktualisierte und erweiterte Auflage. Springer Wien, New York 2011; 348-350.
  • Stummvoll G, Aringer M, Petera P. Primäres Sjögren-Syndrom (PSS). In Dunky A, Graninger W, Herold M, Smolen J, Wanivenhaus A, Hrsg: Praktische Rheumatologie. Fünfte, aktualisierte und erweiterte Auflage. Springer Wien, New York 2011; 351-354
  • Stummvoll G, Aringer M. Antiphospholipid-Antikörper-Syndrom (APS oder APLAS). In Dunky A, Graninger W, Herold M, Smolen J, Wanivenhaus A, Hrsg: Praktische Rheumatologie. Fünfte, aktualisierte und erweiterte Auflage. Springer Wien, New York 2011; 355-358.
  • Aringer M, Graninger W. Familiäres Mittelmeerfieber (FMF). In Dunky A, Graninger W, Herold M, Smolen J, Wanivenhaus A, Hrsg: Praktische Rheumatologie. Fünfte, aktualisierte und erweiterte Auflage. Springer Wien, New York 2011; 610-612.

2010 

Wissenschaftliche Artikel 

  • Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, Cervera R, Doria A, Jayne D, Khamashta MA, Kuhn A, Gordon C, Petri M, Rekvig OP, Schneider M, Sherer Y, Shoenfeld Y, Smolen JS, Talarico R, Tincani A, van Vollenhoven RF, Ward MM, Werth VP, Carmona L. EULAR Recommendations for monitoring systemic lupus erythematosus patients in clinical practice and in observational studies. Ann Rheum Dis 2010; 69: 1269-1274.
  • Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, Cervera R, Dalakas M, Doria A, Hanly JG, Huizinga TW, Isenberg D, Kallenberg C, Piette JC, Schneider M, Scolding N, Smolen J, Stara A, Tassiulas I, Tektonidou M, Tincani A, van Buchem MA, van Vollenhoven R, Ward M, Gordon C, Boumpas DT. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69: 2074-2082.

 

  • Bornhäuser M, Aringer M, Thiede C. Mixed lymphohematopoietic chimerism and response in Wegener's granulomatosis. N Engl J Med 2010; 362: 2431-2432.

 

  • Georgi A, Aringer M. Therapeutic options after nonsuccessful TNF blocker therapy in rheumatoid arthritis. J Miner Stoffwechs 2010; 17: 15-20.

 

  • Aringer M, Kuhn A.  Does cutaneous lupus really exist? Z Rheumatol 2010; 69: 389-392.
  • Winzer M, Aringer M. Use of methotrexate in patients with systemic lupus erythematosus and primary Sjögren's syndrome. Clin Exp Rheumatol 2010; 28: S156-9.

 

  • Aringer M, O’Shea-JJ. Signal Transduction. In Hochberg M, Silman A, Smolen S Weinblatt M, Weisman M, eds:  Rheumatology. Elsevier 2010; 119-124.
  • Tausche AK, Panzner I, Aust D, Wunderlich C. Disabling gout. Lancet 2010; 376: 1093.
  • Jansen TL, Richette P, Perez-Ruiz F, Tausche AK, Guerne PA, Punzi L, Leeb B, Barskova V, Uhlig T, Pimentão J, Zimmermann-Górska I, Pascual E, Bardin T, Doherty M. International position paper on febuxostat. Clin Rheumatol 2010; 29: 835-840.

 

2009 

Wissenschaftliche Artikel 

  • Bauernfeind B, Aringer M, Prodinger B, Kirchberger I, Machold K, Smolen J, Stamm T. Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise. Arthritis Rheum 2009; 61: 21-8. Impact factor 6,787.

 

  • Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M, Ballerin J, Cervera R, Calvo-Alén J, Chizzolini C, Dayer J, Doria A, Ferrario F, Floege J, Guillevin L, Haubitz M, Hiepe F, Houssiau F, Lesavre P, Lightstone L, Meroni P, Meyer O, Moulin B, O'Reilly K, Praga M, Schulze-Koops H, Sinico R, Smith K, Tincani A, Vasconcelos C, Hughes G. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009; 18: 257-263. Impact factor 2,244.

 

  • Karonitsch T, Feierl E, Steiner CW, Dalwigk K, Korb A, Binder N, Rapp A, Steiner G, Scheinecker C, Smolen J, Aringer M. Activation of the Interferon-gamma Signaling Pathway in SLE Peripheral Blood Mononuclear Cells. Arthritis Rheum 2009; 60: 1463-1471. Impact factor 6,787.

 

  • Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS. Adverse events and efficacy of TNF-{alpha} blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009; 48: 1451-1454. Impact factor 4,136.
  • Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, Cervera R, Doria A, Jayne D, Khamashta MA, Kuhn A, Gordon C, Petri M, Rekvig OP, Schneider M, Sherer Y, Shoenfeld Y, Smolen JS, Talarico R, Tincani A, van Vollenhoven RF, Ward MM, Werth VP, Carmona L. EULAR Recommendations for monitoring systemic lupus erythematosus patients in clinical practice and in observational studies. Ann Rheum Dis 2009 Nov 5. [Epub ahead of print] Impact factor 7,188.
  • Aringer M, Smolen J. TNF inhibition in SLE: where do we stand? Lupus 2009; 18: 5-8. Impact factor 2,454.
  • Tausche AK, Jansen TL, Schröder HE, Bornstein SR, Aringer M, Müller-Ladner U. Gout-current diagnosis and treatment. Dtsch Arztebl Int 2009; 106: 549-555. Impact factor 4,257.
  • Winzer M, Tausche AK, Aringer M. Kristall-induzierte Inflammasomaktivierung: Gicht und Pseudogicht. Z Rheumatol 2009; 68: 733-739. Impact factor 0,716.
  • Stummvoll GH, Julius U, Derfler K, Aringer M. Immunoadsorption for systemic lupus erythematosus. Atheroscler Suppl 2009; 10: 110-113. Impact Factor 2,852.

Buch 

  • Aringer M, Hrsg: Antizytokintherapie der rheumatoiden Arthritis. Uni-Med Bremen, London, Boston 2009.

Buchkapitel 

  • Aringer M. Rezeptoren und Signalltransduktion – ein kurzer Überblick. In Aringer M, Hrsg: Antizytokintherapie der rheumatoiden Arthritis. Uni-Med Bremen, London, Boston 2009; 12-15.
  • Tausche AK, Aringer M. Infliximab, Etanercept, Adalimumab (und Golimumab): TNF-Blocker im Vergleich. In Aringer M, Hrsg: Antizytokintherapie der rheumatoiden Arthritis. Uni-Med Bremen, London, Boston 2009; 18-22.
  • Winzer M, Aringer M. Interleukin-6-Rezeptor-Blockade. In Aringer M, Hrsg: Antizytokintherapie der rheumatoiden Arthritis. Uni-Med Bremen, London, Boston 2009; 40-43.
  • Leuchten N, Aringer M. Interleukin-15-Blockade. In Aringer M, Hrsg: Antizytokin-therapie der rheumatoiden Arthritis. Uni-Med Bremen, London, Boston 2009; 46-48.
  • Kleyman O, Aringer M. Interleukin-18-Blockade. In Aringer M, Hrsg: Antizytokin-therapie der rheumatoiden Arthritis. Uni-Med Bremen, London, Boston 2009; 56-57.

2008 

Wissenschaftliche Artikel 

  • Aringer M, Smolen JS.The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008 Jan 23; 10: 202 (Epub ahead of print) Impact factor 4,035. Impact factor 4,035
  • Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu X, Janicijevic B, Smolej-Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A, Donnelly LA, Fairbanks LD, Aringer M, McKeigue PM, Ralston SH, Morris AD, Rudan P, Hastie ND, Campbell H, Wright AF. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.Nat Genet 2008; 40: 437-42. Impact factor 25,556.

 

  • Stummvoll GH, Fritsch RD, Meyer B, Hoefler E, Aringer M, Smolen JS, Steiner G. Characterization of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythematosus.Ann Rheum Dis 2008; 68: 110-116.Impact factor 6,411.

 

  • Jimenez-Boj E, Kedersha N, Tohidast-Akrad M, Karlhofer FM, Stummvoll G, Zimmermann C, Ulrich W, Guiducci S, Hoefler E, Aringer M, Schett G, Matucci-Cerinic M, Smolen JS, Steiner G. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: Increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. Arthritis Rheum 2008; 58: 1226-1236. Impact factor 7,677.

 

  • Aringer M, Feierl E, Smolen J. Cytokine blockade - a promising therapeutic option in SLE. Z Rheumatol. 2008; 67: 315-317. Impact factor 0,651.

 

  • Tausche AK, Aringer M, Schroeder HE, Bornstein SR, Wunderlich C, Wozel G. The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. Am J Med 2008; 121: e3-4. Impact factor 4,907.

 

  • Aringer M, Smolen JS. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf 2008; 7: 411-9. Impact Factor 3,439.

 

  • Aringer M, Crow MK. A Bridge Between Interferon-alpha and Tumor Necrosis Factor in Lupus. J Rheumatol 2008 Aug; 35: 1473-6. Impact factor 3,151

 

  • Aringer M, Graessler J. Understanding deficient elimination of uric acid. Lancet 2008 Sep 30. [Epub ahead of print]. Impact factor 28,638

 

  • Leuchten N, Aringer M. Rheumatoid arthritis today. Internist (Berl) 2008; 49: 1471-82. Impact factor 0,271

 

2007 

Wissenschaftliche Artikel 

  • Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 274-279. Impact factor 6,918.
  • Czirjak L, Nagy Z, Aringer M, Riemekasten G, Matucci-Cerinic M, Furst DE. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007; 66: 966-969.Impact factor 12,811.

 

  • Schueller-Weidekamm C, Schueller G, Aringer M, Weber M, Kainberger F. Impact of sonography in gouty arthritis: Comparison with conventional radiography, clinical examination, and laboratory findings. Eur J Radiol 2007; 62: 437-442. Impact factor 2,462.

 

  • Feierl E, Smolen JS, Karonitsch T, Stummvoll GH, Ekhart H, Steiner CW, Aringer M. Engulfed cell remnants, and not cells undergoing apoptosis, constitute the LE-cell phenomenon.Autoimmunity 2007; 40: 315-321. Impact factor 2,629.

 

  • Stamm TA, Bauernfeind B, Coenen M, Feierl E, Mathis M, Stucki G, Smolen JS, Machold KP, Aringer M. Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. Arthritis Rheum 2007: 57: 1287-1295. Impact factor 6,918.

 

  • Winzer M, Gräßler J, Aringer M. Kristallarthropathien – alt, aber wichtig. Z Rheumatol 2007; 66: 317-325. Impact factor 0,716.
  • Unger S, Tausche AK, Kopprasch S, Bornstein SR, Aringer M, Gräßler J. Molekulare Grundlagen der primär-renalen Hyperurikämie: Zur Rolle des humanen Urattransporter hURAT1. Z Rheumatol 2007; 66: 556-561. Impact factor 0,716.
  • Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: S4-11. Impact factor 2,634.
  • Aringer M, Leuchten N, Machold KP. Frühe rheumatoide Arthritis: Wer schnell hilft, hilft doppelt. Z Rheumatol 2007; 66: 693-702. Impact factor 0,716.
  • Aringer M, Smolen JS. Mixed connective tissue disease: what is behind the curtain? Best Pract Res Clin Rheumatol 2007; 21: 1037-49. Impact factor 3,581.
  • Hermann J, Muller T, Yazdani-Biuki B, Aringer M, Herold M, Ebner W, Ofner P,Graninger W. High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers. Ann Rheum Dis 2007; 66: 561-562.

Buch 

  • Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. Uni-Med Bremen, London, Boston 2007.

 

Buchkapitel 

  •  Aringer M, Redlich K. Cyclophosphamid. In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. Uni-Med Bremen, London, Boston 2007; 34-37.
  • Dörner T, Aringer M. Immunadsorption und Biologicals. In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. Uni-Med Bremen, London, Boston 2007; 48-52.
  • Hiepe F, Aringer M. Basistherapie des nicht-renalen SLE – was ist gesichert? In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. Uni-Med Bremen, London, Boston 2007; 54-56.